Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure

Kidney International

Volumn 56, Issue 6, 1999, Pages 2076-2084

  Frystyk, Jan ^a,b   Ivarsen, Per ^a,b   Skjærbæk, Christian ^a,b   Flyvbjerg, Allan ^a,b   Pedersen, Erling Bjerregaard ^a,b   Ørskov, Hans ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b HOLSTEBRO HOSPITAL   (Denmark)

Author keywords

Creatinine clearance; End stage renal failure; Growth hormone; Tissue catabolism

Indexed keywords

MUSCLE PROTEIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; GROWTH RETARDATION; HORMONE BLOOD LEVEL; HUMAN; KIDNEY CLEARANCE; MALE; METABOLIC CLEARANCE RATE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR DENSITY;

EID: 0033407392     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00798.x     Document Type: Article

References (40)

1. 1. Feld S, Hirschberg R: Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 17:423-480, 1996
2. 2. Tönshoff B, Blum WF, Mehls O: Derangements of the somatotropic hormone axis in chronic renal failure. Kidney Int 58(Suppl): S106-S113, 1997
3. 3. Ørskov H, Christensen NJ: Growth hormone in uremia. Scand J Clin Lab Invest 27:51-60, 1971
4. 4. Haffner D, Schaefer F, Girard J, Ritz E, Mehls O: Metabolic clearance of recombinant growth hormone in health and chronic renal failure. J Clin Invest 93:1163-1171, 1994
5. 5. Veldhuis JD, Iranmanesh A, Wilkowski MJ, Samojlik E: Neuroendocrine alterations in the somatotropic and lactotropic axes in uremic men. Eur J Endocrinol 131:489-498, 1994
6. 6. Barnard R, Waters MJ: The serum growth hormone binding protein: Pregnant with possibilities. J Endocrinol 153:1-14, 1997
7. 7. Blum WF, Ranke MB, Kietzmann K, Tönshoff B, Mehls O: Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. Pediatr Nephrol 5:539-544, 1991
8. 8. Phillips LS, Fusco AC, Unterman TG, Del Greco F: Somatomedin inhibitor in uremia. J Clin Endocrinol Metab 59:764-772, 1984
9. 9. Schwalbe SL, Betts PR, Rayner PH, Rudd BT: Somatomedin in growth disorders and chronic renal insufficiency in children. Br Med J 1:679-682, 1977
10. 10. Tönshoff B, Blum WF, Wingen A, Mehls O: Serum insulin-like growth factors (IGFs) and IGF binding proteins 1, 2 and 3 in children with chronic renal failure: Relationship to height and glomerular filtration rale. J Clin Endocrinol Metab 80:2684-2691, 1995
11. 11. Powell DR, Durham SK, Brewer ED, Frane JW, Watkins SL, Hogg RJ, Mohan S: Effects of chronic renal failure and growth hormone on serum levels of insulin-like growth factor-binding protein-4 (IGFBP-4) and IGFBP-5 in children: A report of the Southwest Pediatric Nephrology Study Group. J Clin Endocrinol Metab 84:596-601, 1999
12. 12. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34, 1995
13. 13. Lee PD, Giudice EC, Conover CA, Powell DR: Insulin-like growth factor binding protein-1: Recent findings and new directions. Proc Soc Exp Biol Med 216:319-357, 1997
14. 14. Lalou C, Lassarre C, Binoux M: A proteolylic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137:3206-3212, 1996
15. 15. Frystyk J, Dinesen B, Ørskov H: Non-competitive lime-resolved immuno-fluorometric assay for determination of human insulin-like growth factor I and II. Growth Regul 5:169-176, 1995
16. 16. Powell DR, Rosenfeld RG, Baker BK, Liu F, Hintz RL: Serum somatomedin levels in adults with chronic renal failure: The importance of measuring insulin-like growth factor I (IGF-I) and IGF-II in acid-chromatographed uremic serum. J Clin Endocrinol Metab 63:1186-1192, 1986
17. 17. Blum WF, Ranke MB, Bierich JR: A specific radioimmunoassay for insulin-like growth factor II: The interference of IGF binding proteins can be blocked by excess IGF-I. Acta Endocrinol (Copenh) 118:374-380, 1988
18. 18. Frystyk J, Skjærbæk C, Dinesen B, Ørskov H: Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett 348:181-191, 1994
19. 19. Hossenlopp P, Seurin D, Segovia Quinson B, Hardouin S, Binoux M: Analysis of serum insulin-like growth factor binding proteins using Western blotting: Use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 154:138-143, 1986
20. 20. Skjærbæk C, Kaal A, Møller J, Vahl N, Weeke J, Ørskov H, Flyvbjerg A: No effect of growth hormone on serum insulin-like growth factor binding protein-3 proteolysis. J Clin Endocrinol Metab 83:1206-1210, 1998
21. 21. Lamson G, Giudice LC, Rosenfeld RG: A simple assay for proteolysis of IGFBP-3. J Clin Endocrinol Metab 72:1391-1393, 1991
22. 22. Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS: Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 82:2308-2313, 1997
23. 23. Rabkin R, Fervenza FC, Maidment H, Ike J, Hintz R, Liu F, Bloedow DC, Hoffman AR, Gesundheit N: Pharmacokinetics of insulin-like growth factor-I in advanced chronic renal failure. Kidney Int 49:1134-1140, 1996
24. 24. Bereket A, Lang CH, Blethen SL, Kaskel FJ, Stewart C, Wilson TA: Growth hormone treatment in growth retarded children with end stage renal failure: Effect on free/dissociable IGF-I levels. J Pediatr Endocrinol Metab 10:197-202, 1997
25. 25. Baxter RC, Skriver L: Altered ligand specificity of proteolysed insulin-like growth factor binding protein-3. Biochem Biophys Res Commun 196:1267-1273, 1993
26. 26. Blat C, Villaudy J, Binoux M: In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest 93:2286 2290, 1994
27. 27. Chapman IM, Hartmen ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL, Thorner MO: Recovery of growth hormone release from suppression by exogenous insulin-like growth factor-I (IGF-I): Evidence for a suppressive action of free rather than bound IGF-I. J Clin Endocrinol Metab 83:2836-2842, 1998
28. 28. Powell DR, Liu F, Baker BK, Hintz RL, Lee PD, Durham SK, Brewer ED, Frane JW, Watkins SL, Hogg RJ: Modulation of growth factors by growth hormone in children with chronic renal failure: The Southwest Pediatric Nephrology Study Group. Kidney Int 51:1970-1979, 1997
29. 29. Tönshoff B, Powell DR, Zhao D, Durham SK, Coleman ME, Domene HM, Blum WF, Baxter RC, Moore LC, Kaskel FJ: Decreased hepatic insulin-like growth factor (IGF)-I and increased IGF binding protein-1 and -2 gene expression in experimental uremia. Endocrinology 138:938-446, 1997
30. 30. Haffner D, Tönshoff B, Blum WF, Vickers M, Siebler T, Cronin MJ, Baxter RC, Mehls O: Insulin-like growth factors (IGFs) and IGF binding proteins, serum acid-labile, subunit and growth hormone binding protein in nephrotic children. Kidney Int 52:802-810, 1997
31. 31. Schmitz O, Alberti KGMM, Christensen NJ, Hasling C, Hjøllund E, Beck-Nielsen H, Ørskov H: Aspects of glucose homeostasis in uremia as assessed by the hyperinsulinemic euglycemic clamp technique. Metabolism 34:465-473, 1985
32. 32. Lee DY, Park SK, Yorgin PD, Cohen P, Youngman O, Rosenfeld RG. Alteration in insulin-like growth factor binding proteins (IGFBPs) and IGFBP-3 protease activity in scrum and urine from acute and chronic renal failure. J Clin Endocrinol Metab 79:1376-1382, 1994
33. 33. Holly JM, Claffey DC, Cwyfan Hughes SC, Frost VJ, Yateman ME: Proteases acting on IGFBPs: Their occurrence and physiological significance. Growth Regul 3:88-91, 1993
34. 34. Bang P: Serum proteolysis of IGFBP-3. Prog Growth Factor Res 6:285-292, 1995
35. 35. Skjærbæk C, Frystyk J, Ørskov H, Kissmeyer NP, Jensen MB, Laurberg S, Møller N, Flyvbjerg A: Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: The possible role of insulin-like growth factor-binding protein-3 proteolysis. J Clin Endocrinol Metab 83:2445-2449, 1998
36. 36. Hasegawa T, Hasegawa Y, Takada M, Tsuchiya Y: The free form of insulin-like growth factor I increases in circulation during normal human pregnancy. J Clin Endocrinol Metab 80:3284-3286, 1995
37. 37. Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, Binoux M: Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab 71:797-805, 1990
38. 38. Powell DR, Rosenfeld RG, Sperry JB, Baker BK, Hintz RL: Serum concentrations of insulin-like growth factor (IGF)-1, IGF-2 and unsaturated somatomedin carrier proteins in children with chronic renal failure. Am J Kidney Dis 10:287-292, 1987
39. 39. Thissen JP, Ketelslegers JM, Underwood LE: Nutritional regulation of the insulin-like growth factors. Endocr Rev 15:80-101, 1994
40. 40. Frystyk J, Vestbo E, Skjærbæk C, Mogensen CE, Ørskov H: Free insulin-like growth factors in human obesity. Metabolism 44(Suppl 4): 37-44, 1995